The purpose of the study is to determine the efficacy of gefitinib (IressaTM) in combination with radiotherapy on patients with glioblastoma multiforme.

Inclusion Criteria:

• Signed informed consent
• histologically-or cytologically-confirmed glioblastoma multiforme
• age 18 years or older

Exclusion Criteria:

• Have had prior radiation therapy, immunotherapy, gene therapy and/or chemotherapy for the glioblastoma
• co-existing malignancies or malignancies diagnosed within the last 5 years with the exception of basal cell carcinoma or cervical cancer in situ
• known severe hypersensitivity to ZD1839 or any of the excipients of this product.